A growing number of neutrophil-derived cytokines have proven to be crucial to various inflammatory and immune processes in vivo. Whereas C/EBP (CCAAT/enhancer-binding protein) transcription factors are important for neutrophil differentiation from myeloid precursors, we report herein that they also regulate cytokine production in mature neutrophils. All known C/EBP proteins but C/EBP␥ are expressed in neutrophils; most isoforms localize to the nucleus, except for C/EBP␣, which is cytoplasmic. Neutrophil stimulation does not alter the overall levels, cellular distribution, or turnover of C/EBP proteins; it also does not further induce the constitutive DNA-binding activity detected in nuclear extracts, consisting of C/EBP␤ and C/EBP. However, nuclear C/EBP␤ is rapidly phosphorylated upon cell stimulation, suggesting that it can activate cytokine promoters. Indeed, the transactivation of an IL-8 promoter-luciferase construct in a human neutrophil-like cell line was impaired when its C/EBP or NF-B sites were mutated. Overexpression of a C/EBP repressor also impeded IL-8 promoter transactivation, as well as the generation of IL-8, Mip-1␣, and Mip-1␤ in this cellular model, whereas TNF-␣ generation was mostly unaffected. Finally, overexpression of a C/EBP␤ mutant (T235A) as well as chromatin immunoprecipitation assays unveiled an important role for this residue in cytokine induction. This is the first demonstration that C/EBP factors are important regulators of cytokine expression in human neutrophils.
N eutrophils are a cornerstone of innate immunity, in view of their phagocytic and microbicidal activities. In addition to being professional phagocytes, neutrophils produce a wide array of inflammatory mediators (principally cytokines and chemokines), which are involved in both innate and acquired immunity (1, 2) . Studies conducted in other cell types have revealed that a critical step in the regulation of these mediators is the transcriptional activation of the corresponding genes by three major families of transcription factors; that is, the NF-B, AP-1, and C/EBP (CCAAT/enhancer-binding protein) 3 families. In neutrophils, we have shown that the induction of cytokine and chemokine production correlates well with, and depends on, NF-B activation (3) (4) (5) , whereas it appears to be independent of AP-1 (6 -8) . By contrast, a role for C/EBP transcription factors in neutrophil cytokine generation remains to be demonstrated.
The C/EBP family encompasses six members, termed ␣, ␤, ␦, , ␥, and . Additionally, several isoforms of C/EBP␣, C/EBP␤, and C/EBP can be generated through alternative splicing, different promoter usage, different usage of translation initiation codon from the same mRNA, or by regulated proteolysis (9) . The shorter isoforms of C/EBP␣, C/EBP␤, C/EBP, and C/EBP␥ generally act as inhibitors or have lower promoter activation potential, since their transactivation domain is partially or totally missing (9) . All members of the family can homo-or heterodimerize through their basic leucine zipper region, at least in vitro (9) . The activity of C/EBP proteins can be regulated in two major ways, that is, by modulating their cellular levels (through gene transcription, mRNA translation, or proteolysis) and/or by phosphorylation in a negative regulatory domain, which is thought to relieve the inhibition of their DNA-binding and transactivation domains (10, 11) . In this regard, all C/EBP proteins but C/EBP␥ have been reported to be phosphorylation targets; among them, C/EBP␤ phosphorylation has been the most extensively studied (9, (12) (13) (14) .
Although C/EBP proteins are widely expressed, the expression of some members is up-regulated under particular circumstances. For instance, C/EBP␣ is strongly expressed in early myeloid progenitors (15) , and hematopoietic cells of C/EBP␣-deficient mice are blocked at an early stage of granulocyte development (16) . Similarly, C/EBP expression is high during granulocytic differentiation (17) , and myeloid progenitors are blocked at the last stage of neutrophil maturation in C/EBP-deficient mice (18) . In addition to their involvement in neutrophil development and maturation, C/EBP proteins reportedly participate in the regulation of numerous inflammatory cytokines in various cell types, including TNF-␣, IL-1␤, IL-12, IL-8, and Mip-1␣/␤ (19 -25) , which can all be induced in neutrophils (2) . Despite this, all that is known about C/EBP proteins in mature human neutrophils is that the C/EBP␤, ␦, , and isoforms are expressed (26, 27) .
In this study, we report on the expression, stability, subcellular localization, DNA binding activity, and phosphorylation of C/EBP transcription factors in human neutrophils. Importantly, we also demonstrate their involvement in IL-8 promoter transactivation and in the generation of several inflammatory cytokines. We also show that C/EBP␤ and C/EBP are already bound to the IL-8 promoter in primary human neutrophils, and that chromatin-bound C/EBP␤ is rapidly phosphorylated upon cell stimulation. Thus, C/EBP proteins are required not only for neutrophil differentiation, but also for the inducible expression of cytokines (and probably other inflammatory mediators) in human neutrophils.
Materials and Methods

Abs and reagents
Abs raised against C/EBP␤ (no. 3082), C/EBP␦ (no. 2318), and phospho-C/EBP␤ (no. 3084) were from Cell Signaling Technology; Abs against IB-␣ (sc-371), C/EBP␣ (sc-61, sc-15384), C/EBP␤ (sc-150), C/EBP (sc-158), C/EBP␥ (sc-7658), and C/EBP (sc-793) were from Santa Cruz Biotechnology. Luciferase contructs under the control of the IL-8 promoter (IL-8WT), as well as mutants in the NF-B site (IL-8⌬B) or in the NF-IL6 site (IL-8⌬NF-IL6), were a kind gift from Dr. Allan R. Brasier (University of Texas Medical Branch, Galveston, TX) (28) . The luciferase construct driven by five consensus C/EBP sites cloned into pGL3 (pGL3-5xC/ EBP) was from Dr. Jean-René Cardinaux (Université de Lausanne, Lausanne, Switzerland) (29) . The luciferase construct driven by five consensus NF-B sites (pNF-B-Luc) was from Stratagene. The plasmid encoding dominant-negative (dn) IB␣ (S32,36A) was a gift from Dr. Christian Jobin (University of North Carolina, Chapel Hill, NC). The C/EBP repressor, A-CEBP, cloned into pRc/CMV500 was obtained from Dr. Charles Vinson (National Cancer Institute, Bethesda, MD) (30) , and was used as such or subcloned (minus the Flag epitope) into pCMV2N3T (which contains two nuclear localization signal sequences and three hemagglutinin tags), obtained from Dr. Didier Trouche (Université Paul-Sabatier, Toulouse, France). Plasmids encoding wild-type C/EBP␤ (CMV-NFIL6) and a mutant form (T235A) were from Dr. S. Akira (Osaka University, Japan). Ficoll-Paque, T4 polynucleotide kinase, and poly(dI: dC) were from Amersham Biosciences; radionucleotides were from NEN. Endotoxin-free (Ͻ2 pg/ml) RPMI 1640 and FCS were from Sigma-Aldrich and Wisent, respectively. Recombinant human cytokines were from R&D Systems, and ultrapure LPS (from Escherichia coli 0111:B4) was from InvivoGen. Acetylated BSA, cycloheximide, diisopropylfluorophosphate (DFP), DMSO, fMLP, and PMSF were from Sigma-Aldrich. The protease inhibitors aprotinin, 4-(2-aminomethyl)benzenesulfonyl fluoride (AEBSF), leupeptin, and pepstatin A were all from Roche. All other reagents were of the highest available grade, and all buffers and solutions were prepared using pyrogen-free clinical grade water.
Cell isolation and culture
Neutrophils were isolated from the peripheral blood of healthy donors, following a protocol that was duly approved by an institutional ethics committee. The entire procedure was conducted at room temperature and under endotoxin-free conditions, as described previously (31) . Purified neutrophils were resuspended in RPMI 1640 supplemented with 10% autologous serum, at a final concentration of 5 ϫ 10 6 cells/ml (unless otherwise stated). As determined by Wright staining and FACS analysis, the final neutrophil suspensions contained Ͻ0.5% monocytes or lymphocytes; neutrophil viability was Ͼ98% after up to 4 h in culture, as determined by trypan blue exclusion and by annexin V/propidium iodide FACS analysis.
The PLB-985 cell line (obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen) was cultured at 37°C under a humidified 5% CO 2 atmosphere in RPMI 1640 containing 10% FCS, 100 U/ml penicillin, and 100 g/ml streptomycin. Granulocytic differentiation was induced by the inclusion of culture-grade DMSO (1.25% v/v) in the culture medium for 5 days, as described (8) .
Immunoblots
Cells were incubated at 37°C in the presence or absence of stimuli. Incubations were stopped by adding equivalent volumes of ice-cold PBS supplemented with DFP (2 mM, final concentration) and phosphatase inhibitors (10 mM NaF, 1 mM Na 3 VO 4 , 10 mM Na 4 P 2 O 7 ). For whole-cell samples, boiling sample buffer was added directly to cell pellets, which were briefly vortexed and placed in boiling water for a further 5 min. Samples thus prepared were sonicated to disrupt chromatin and stored at Ϫ20°C before analysis. When cytoplasmic and nuclear fractions were prepared, incubations were stopped as described above, and neutrophils were disrupted by nitrogen cavitation as described previously (3, 4) . This procedure was shown to yield nuclear and cytoplasmic fractions that are exempt from cross-contamination (3, 31) . Samples were electrophoresed, transferred onto nitrocellulose, and processed for immunoblot analysis as previously described (3) .
EMSAs
Cells were incubated as described above and resuspended in ice-cold relaxation buffer (10 mM PIPES (pH 7.30), 10 mM NaCl, 3.5 mM MgCl 2 , 0.5 mM EGTA, 0.5 mM EDTA, 1 mM DTT) supplemented with an antiprotease cocktail (1 mM DFP, 1 mM PMSF, 1 mM AEBSF, and 10 g/ml each of aprotinin, leupeptin, and pepstatin A, final concentrations) and the aforementioned phosphatase inhibitors. Nuclear extracts were then prepared using a nitrogen bomb procedure, which we described previously (3, 4) , and subsequently analyzed in EMSA as described earlier (3).
Real-time PCR analyses
For each experimental condition, total RNA was extracted from 10 7 neutrophils using TRIzol (Invitrogen); 1 g of the resulting RNA was then reverse transcribed using SuperScript II (Invitrogen) and random decamers (Ambion). Oligonucleotide primers were as follows: IL-8 (forward, AG GAAGCTCACTGGTGGCTG; reverse, TAGGCACAATCCAGGTGGC); Mip-1␣ (forward, AGCTGACTACTTTGAGACGAGCA; reverse, CGGCT TCGCTTGGTTAGGA); Mip-1␤ (forward, CTGCTCTCCAGCGCTC TCA; reverse, GTAAGAAAAGCAGCAGGCGG); TNF-␣ (forward, TC TTCTCGAACCCCGAGTGA; reverse, CCTCTGATGGCACCACCAG); GAPDH (forward, CGAGATCCCTCCAAATC; reverse, TTCACACCCA TGACGAAC). Duplicate real-time PCR reactions for each sample were performed in a volume of 20 l containing 50 ng cDNA and 200 nM forward/reverse primers, using a QuantiTect SYBR Green quantitative PCR kit (Qiagen) in a Rotor-Gene 3000 instrument (Corbett Research). Reaction conditions for all primer sets were as follows: 95°C for 3 min, followed by 35 cycles (95°C for 15 s, 60°C for 20 s, 72°C for 30 s). Amplification plots were generated using the Rotor-Gene application software v6.0 (Corbett Research), and fold induction was calculated using the ⌬⌬C t method with GAPDH as a housekeeping gene (32) .
ELISA analysis of secreted proteins
Cells were cultured in 12-well culture plates at 37°C under a 5% CO 2 atmosphere, in the presence or absence of stimuli and/or inhibitors, for the indicated times. Culture supernatants were analyzed in ELISA using commercially available capture and detection Ab pairs (R&D Systems, BD Pharmingen).
Transient transfections and luciferase assays
PLB-985 granulocytes were nucleofected mostly as described (8) . Briefly, 10 7 cells were pelleted and resuspended in 100 l of room temperature human dendritic cell Nucleofector solution (Amaxa Biosystems), and 5 g of plasmid was added. After a 5-min incubation, the cells were nucleofected using the Q-01 setting of a Nucleofector instrument (Amaxa Biosystems). Cells were then centrifuged (280 ϫ g, 10 min), resuspended at 2 ϫ 10 6 /ml in RPMI 1640 medium supplemented with 10% FCS, and laid to rest for 2.5 h. Cells were then cultured in the presence or absence of stimuli for 1 h (mRNA analyses) or 6 h (cytokine secretion and luciferase assays). Luciferase assays were conducted as described (8) .
Chromatin immunoprecipitation (ChIP) assays
Chromatin preparation and immunoprecipitation were performed using the EZ-ChIP kit, according to the manufacturer's protocol (Upstate Biotechnology). Briefly, protein-DNA cross-linking was achieved by incubating neutrophils (2 ϫ 10 7 cells per condition) with 1% formaldehyde for 10 min at room temperature under gentle agitation. Cross-linking was stopped by adding glycine to a final concentration of 0.125 M and incubating at room temperature for another 5 min. Cells were pelleted and washed in cold PBS containing protease and phosphatase inhibitors. Pellets were resuspended in 1 ml lysis buffer (Upstate Biotechnology) and chromatin was then sonicated to an average length of 0.2-1 kb using a Sonic Dismembrator, model 100 (Fisher Scientific). Sonicated chromatin (100 l/condition) was then immunoprecipitated with anti-C/EBP␤, anti-C/EBP, or anti-phospho-C/EBP␤ Abs, or with isotypematched control Abs coupled to microbeads. The resulting protein-DNA complexes were then eluted before reversing the protein-DNA cross-linking to allow for DNA recovery. Samples were analyzed by conventional PCR or quantitative PCR to amplify regions containing the proximal C/EBP site in the IL-8 promoter, using the following primers: IL-8 (Ϫ190): 5Ј-AAGAAAACTTTCGTCATACGTCCG-3Ј and IL-8 (Ϫ20): 5Ј-TGGCTTTTTATATCATCACCCTAC-3Ј. Results were expressed as fold enrichment normalized to input.
Data analysis
All data are represented as the means Ϯ SEM of at least three independent experiments. Statistical differences between groups were analyzed by oneway ANOVA, followed by Bonferroni's post hoc test, using GraphPad Prism 5 software.
Results
Expression and distribution of C/EBP proteins in human neutrophils
To determine which C/EBP isoforms are expressed by neutrophils, unstimulated cells were boiled in sample buffer and processed for immunoblotting using isoform-specific Abs. As shown in Fig. 1A , neutrophils express most known C/EBP isoforms, albeit with variable intensity. Moderate amounts of C/EBP␣ (both the p30 and p43 variants), C/EBP␦, and C/EBP are expressed, compared with substantial quantities of C/EBP␤ (especially the LAP and LIP variants) and C/EBP (especially the p14 and p32 variants, in that order). In contrast, authentic C/EBP␥ was not detected, even when up to 3 ϫ 10 6 cell equivalents were loaded on the gels, or when the films were deliberately overexposed ( Fig. 1A and data not shown).
We next examined the subcellular distribution of the C/EBP proteins. Neutrophils were disrupted by nitrogen cavitation, and the resulting nuclear and cytoplasmic fractions were analyzed by immunoblot; we previously showed that this fractionation procedure yields cytoplasmic fractions and intact nuclei that are exempt from cross-contamination (5, 31). As shown in Fig. 1B , most C/EBP isoforms are strictly nuclear, with the exception of C/EBP␣, and of the p14 variant of C/EBP. Cell stimulation with various neutrophil agonists did not alter the cellular distribution of the various C/EBP proteins (data not shown).
Because the expression of some C/EBP proteins (namely, ␤ and ␦) can increase following cell stimulation in monocytes and macrophages (25, 33-37), we examined whether neutrophil stimulation might similarly affect C/EBP protein levels. Neutrophils were stimulated for up to 4 h with LPS or TNF-␣ before immunoblot analysis of their C/EBP proteins. The cellular levels of most C/EBP isoforms were largely unaffected by simulation with any of the above stimuli, as shown in Fig. 2A for LPS. A notable exception was C/EBP␦, whose expression decreased with time and was barely detectable at 120 min, both in resting and stimulated cells (Fig. 2B) . In view of recent reports showing that C/EBP␦ can be constitutively degraded via the ubiquitin-proteasome pathway (38, 39) , neutrophils were treated in the presence or absence of the proteasome inhibitor, MG-132, and cultured for 2 h. As shown in Fig. 2C , MG-132 pretreatment largely prevented the constitutive loss of the C/EBP␦ protein; similar results were obtained in cells stimulated with either LPS or TNF (data not shown).
Finally, most of the C/EBP proteins expressed in neutrophils were found to have a low turnover. Indeed, the cellular levels of C/EBP␣, C/EBP␤, C/EBP, and C/EBP remained largely unchanged following a 4-h incubation of the cells in the presence of cycloheximide (Fig. 2D) . In the case of C/EBP␦, the constitutive loss of the protein not did not occur at a faster rate in the presence of cycloheximide (Fig. 2D) . Similar results were obtained in cells stimulated with either LPS or TNF (data not shown). By comparison, IB␣ was found to have a high turnover rate in unstimulated neutrophils, in agreement with our previous reports (3, 6, 31) .
Detection of C/EBP DNA-binding activities in human neutrophils
Because cell stimulation can induce the binding of C/EBP DNAbinding complexes in several cell types (25, 36, 40) , neutrophils were exposed for varying lengths of time to various stimuli before nuclear extract preparation and EMSA analysis. As shown in Fig.  3A , constitutive NF-B and C/EBP DNA-binding activities are detectable in neutrophil extracts. Whereas NF-B binding is strongly and transiently increased in response to LPS, as we originally described (3), C/EBP binding remains unchanged for up to 60 min of LPS stimulation, and it is consistently lost by 120 min (Fig. 3A) . Similar results were obtained in cells stimulated with TNF-␣ (data not shown).
The neutrophil C/EBP and NF-B DNA-binding complexes were specific, since they were competed out by a 25-fold excess of unlabeled probes, but they were unaffected by a 50-fold excess of unlabeled oligonucleotides in which the DNA-binding sequence was mutated (Fig. 3B, last two lanes of each panel) . Supershift analyses further revealed that the C/EBP complex contains C/EBP␤ and C/EBP, both in resting or activated neutrophils (Fig.  3B and data not shown) . By comparison, the NF-B complex was supershifted by p50 and RelA Abs, as reported before (3).
Detection of phosphorylated C/EBP␤ in human neutrophils
The activation of C/EBP dimers is not always reflected by an increased DNA-binding activity, and phosphorylation of C/EBP␤ on Thr 235 reportedly leads to increased promoter activation potential (12) (13) (14) . Since C/EBP␤ is a major component of the constitutive C/EBP complex of neutrophil extracts, we next investigated its phosphorylation status on Thr 235 . As shown in Fig. 4A , C/EBP␤ was transiently phosphorylated in response to LPS or TNF-␣; this effect was already evident after 5-10 min and was sustained for up to 1 h (depending on the donor). We also investigated whether the C/EBP DNA-binding complexes contained phosphorylated C/EBP␤ by performing supershift analyses using a phosphoThr 235 C/EBP␤ Ab. In agreement with our immunoblot data, phosphorylated C/EBP␤ was present in the DNA-binding complexes of LPS-stimulated neutrophils, whereas it was undetectable in extracts from resting cells (Fig. 4B) .
Functional impact of C/EBP factors on cytokine expression in a human neutrophil-like cell line
In view of our findings that C/EBP␤ can be inducibly phosphorylated and that it is present in neutrophil C/EBP complexes, we sought to determine whether C/EBP proteins may affect neutrophil transcriptional activation. To this end, we used the myeloid cell line PLB-985, which can be differentiated into neutrophil-like cells, based on morphology and acquisition of functional responses such as a respiratory burst and degranulation (41, 42) . Moreover, the cytokine expression pattern and transcription factor binding pattern of granulocytic PLB-985 cells are undistinguishable from those of primary neutrophils (Ref. 8 and supplemenal Fig. 1A ). 4 Supershift analyses additionally revealed that the NF-B and C/EBP complexes of granulocytic PLB-985 cells contain the same constituents as those from primary neutrophils, except for the additional presence of some C/EBP␣ in the PLB-985 extracts (supplemental Fig. 1B) . Finally, C/EBP␤ was rapidly phosphorylated in response to LPS or TNF-␣ in granulocytic PLB-985 cells (supplemental Fig. 1C ), again as observed in primary neutrophils (Fig.  4A) . Thus, differentiated PLB-985 cells closely resemble human neutrophils with respect to their C/EBP system.
To determine whether C/EBP proteins affect promoter activation, granulocytic PLB-985 cells were nucleofected with luciferase constructs under the control of repeated C/EBP or NF-B elements, before stimulation with LPS or TNF-␣. As shown in Fig.  5A , this resulted in a significant increase in both C/EBP-and NF-B-driven promoter activity. We next investigated whether C/EBP can activate an actual chemokine promoter. Neutrophil-like PLB-985 cells were nucleofected with a construct containing the IL-8 4 The online version of this article contains supplemental material. promoter coupled to a luciferase reporter gene, or with similar IL-8 promoter constructs featuring mutations in the proximal NF-B or C/EBP sites. As shown in Fig. 5B , mutation of the NF-B site considerably decreased constitutive IL-8 promoter activity, while mutation of the C/EBP ("NF-IL6") site had no significant effect. Thus, NF-B seems important for basal promoter activity. Fig. 5B also shows that the cells responded to either LPS or TNF with a substantial activation of the IL-8 promoter. In stimulated cells, mutation of the proximal NF-B or C/EBP sites nearly abolished promoter inducibility (Fig. 5B) . Thus, it appears that C/EBP factors are important for inducible IL-8 promoter activity in human neutrophil-like cells.
To exclude the possibility that unrelated transcription factors might bind the NF-B and C/EBP elements within the IL-8 promoter, we overexpressed dominant negatives of both pathways into granulocytic PLB-985 cells. As shown in Fig. 6A (left panel) , dn IB␣ (S32,36A) largely prevented the induction of a B-driven promoter, as expected. The activation of the IL-8 promoter was similarly affected by dn IB␣ overexpression Fig. 6A (right panel) . Thus, NF-B factors are involved in the induction of the IL-8 gene in human granulocytes, in keeping with our previous observations (5, 8) . Neutrophil-like PLB-985 cells were also made to overexpress a specific C/EBP repressor protein, A-CEBP, which readily heterodimerizes with C/EBP isoforms to form dysfunctional heterodimers (30) . After having determined that A-CEBP overexpression was maximal at ϳ4 h (supplemental Fig. 2A) , we assessed the effect of A-CEBP overexpression on C/EBP DNA binding and inducible chemokine production. Disappointingly, A-CEBP overexpression failed to affect either response (supplemental Fig. 2C , left panel, and data not shown). This prompted us to examine the cellular distribution of overexpressed A-CEBP. As shown in supplemental Fig. 2A , A-CEBP was strictly cytoplasmic and therefore had little chance to interact with nuclear C/EBP isoforms. As a result, we subcloned the A-CEBP repressor into the pCMV2N3T vector, so that the resulting protein (hereafter referred to as A-CEBP2N3T) would acquire nuclear localization sequences. As shown in supplemental Fig. 2B , overexpressed A-CEBP2N3T localized to both the cytoplasm and nucleus of granulocytic PLB-985 cells, with a maximal expression being achieved at (IL-8 ⌬NFIL6) . The cells were then cultured for 6 h at 37°C in the presence or absence of 100 ng/ml LPS (upper panel) or 100 U/ml TNF-␣ (lower panel) before cell lysis and luciferase activity measurement. Mean Ϯ SEM from seven independent experiments. ‫,ءءء‬ p Ͻ 0.001. ϳ2 h. As shown in supplemental Fig. 2C (right panel) , constitutive C/EBP DNA-binding activities were markedly diminished by A-CEBP2N3T overexpression, whereas LPS-induced NF-B DNA binding was unaffected. Finally, overexpression of either A-CEBP or A-C/EBP2N3T abrogated the induction of C/EBP-driven promoter activity in RAW 264.7 cells (supplemental Fig. 2D) , showing that our A-CEBP2N3T construct is functionally equivalent to original A-CEBP. A similar experiment conducted in granulocytic PLB-985 cells showed that overexpression of A-C/EBP2N3T also profoundly impeded C/EBP-driven promoter activation (Fig. 6B, left panel) . Thus, A-C/EBP2N3T acts as a highly effective dominant-negative modulator of C/EBP-dependent gene transactivation in our cellular model.
Cotransfection of A-C/EBP2N3T with the IL-8 wild-type promoter into granulocytic PLB-985 cells largely prevented the induction of IL-8 promoter activity (Fig. 6B, right panel) . As a control, we also cotransfected A-C/EBP2N3T with the IL-8 promoter featuring a mutated C/EBP site. As shown in Fig. 6B (bottom  panel) , A-C/EBP2N3T overexpression did not affect the inducibility of the mutated promoter, which strongly suggests that the actions of our A-C/EBP2N3T construct are restricted to the C/EBP system. We finally investigated whether C/EBP transcription factors participate in the inducible production of other inflammatory cytokines (besides IL-8) in neutrophil-like PLB-985 cells. As shown in Fig. 7A , A-CEBP2N3T overexpression strongly inhibited the inducible gene expression of IL-8, Mip-1␣, and Mip-1␤, whereas that of TNF-␣ was only moderately affected. The release of the corresponding cytokines was similarly affected by A-CEBP2N3T overexpression (Fig. 7B and data not shown) . (d5) were co-nucleofected with plasmids encoding dn IB-␣ (S32,36A) or its empty vector (mock) and a luciferase-reporter construct (either pNF-B-Luc or or IL-8WT). After a 2.5-h culture, the cells were stimulated for 6 h with 100 ng/ml LPS, lysed, and luciferase activity was measured. B, Granulocytic PLB-985 cells (d5) were co-nucleofected with plasmids encoding a dn C/EBP construct (A-C/EBP2N3T) and a luciferase-reporter construct (pGL3-5XC/EBP-Luc, IL-8WT, or IL-8⌬NF-IL6). After a 2.5-h culture, the cells were stimulated for 6 h with 100 ng/ml LPS, lysed, and luciferase activity was measured. Data are mean Ϯ SEM from at least three independent experiments. ‫,ءءء‬ p Ͻ 0.001.
FIGURE 7.
Effect of an overexpressed C/EBP repressor on cytokine expression and release in neutrophil-like PLB-985 cells. A, Granulocytic PLB-985 cells (d5) were nucleofected with a plasmid encoding a dn A-CEBP repressor (A-C/EBP2N3T). After a 2.5-h culture, the cells were stimulated for 1 h with 100 ng/ml LPS before RNA extraction and quantitative PCR analysis. Values were normalized over GAPDH and are represented as fold increase relative to unstimulated cells. Mean Ϯ SEM from three independent experiments, each performed in duplicate. B, Granulocytic PLB-985 cells (d5) were nucleofected with a plasmid encoding A-C/ EBP2N3T. After a 2.5-h culture, the cells were stimulated for 6 h with 100 ng/ml LPS or 100 U/ml TNF-␣ before ELISA analysis of culture supernatants. Mean Ϯ SEM from three independent experiments. ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01; ‫,ءءء‬ p Ͻ 0.001; ns, not significant; nd, not determined. 
Chromatin association of phosphorylated C/EBP␤ (Thr 235 ) in human neutrophils and functional consequences of C/EBP␤ phosphorylation on cytokine generation
We next sought to gather more evidence of a link between the rapid onset of C/EBP␤ phosphorylation observed in neutrophils and granulocytic PLB-985 cells, and the C/EBP-dependent chemokine promoter activation. To this end, ChIP assays were performed in primary human neutrophils, using primers targeting the region of the IL-8 promoter encompassing the proximal C/EBP site. As shown in Fig. 8 , C/EBP␤ and C/EBP proteins are constitutively bound to the IL-8 promoter, both in resting and LPSactivated neutrophils. Importantly, however, the association of phosphorylated C/EBP␤ to the IL-8 promoter is enhanced 4-to 5-fold following LPS stimulation. These results prompted us to determine the actual impact of the inducible phosphorylation of C/EBP␤ on cytokine production. For this purpose, neutrophil-like PLB-985 cells were made to overexpress a C/EBP␤ variant in which Thr 235 had been mutated to an alanine or (as a control) to wild-type C/EBP␤. As shown in Fig. 9 , the production of IL-8, Mip-1␣, and (to a lesser extent) Mip-1␤ was increased in cells overexpressing wild-type C/EBP␤, whereas TNF-␣ production was unaffected. This increase in chemokine production was, however, abolished in cells overexpressing C/EBP␤ (⌻235〈). Therefore, phosphorylation of C/EBP␤ on Thr 235 seems to be essential for inducible IL-8, Mip-1␣, and Mip-1␤ gene expression in neutrophils.
Discussion
Cytokines and chemokines released by neutrophils contribute significantly to the recruitment of discrete leukocyte populations at inflammatory sites and modulate inflammatory and immune processes (1, 2). The production of these mediators must therefore be tightly regulated. In this regard, we recently showed that the production of inflammatory cytokines by human neutrophils is under the control of NF-B (5), and that, accordingly, overexpression of a dn IB␣ impedes both cytokine expression (8) and IL-8 promoter transactivation in human granulocytes (this paper). In contrast, neutrophil cytokine production appears to be independent of AP-1 (6 -8). We now report that C/EBP transcription factors, in addition to their known involvement in the differentiation of myeloid precursors into granulocytes (15) (16) (17) (18) 43) , also play a foremost role in regulating the inducible production of several inflammatory cytokines in mature human neutrophils.
We first investigated which members of the C/EBP proteins family are expressed in neutrophils, since the existing literature contains conflicting observations. Earlier studies had reported that neither C/EBP␣ nor C/EBP␤ proteins are detectable in neutrophil nuclear extracts, be it in resting cells or following stimulation with TNF-␣ or LPS, and that, accordingly, no DNA binding to a C/EBP probe could be detected in EMSA (44, 45) . However, it should be noted that in these studies, nuclear extracts were prepared following cell disruption by detergent lysis in the absence of elastaseclass protease inhibitors, a procedure that results in the proteolysis of many neutrophil transcription factors (4). In contrast, low amounts of C/EBP␣ and abundant quantities of C/EBP␤ were detected in neutrophils by Bjerregaard et al. (27) , who included an inhibitor of elastase-class proteases (DFP) in their samples, in complete agreement with our results. The presence of low amounts of C/EBP␣ in mature neutrophils is also in keeping with the observation that the protein is highly expressed in early myeloid progenitors, whereas its levels markedly decrease during terminal granulocytic differentiation (15, 27, 46) . We observed a similar phenomenon during the differentiation of PLB-985 cells toward a neutrophil-like phenotype (our unpublished data). Our data regarding the presence of other C/EBP isoforms in neutrophils (namely, moderate C/EBP␦ and C/EBP expression, and undetectable C/EBP␥) also agree well with those of Bjerregaard et al. (27) , albeit with one notable exception. Using magnetic purification, the latter group attributed the previous detection of C/EBP isoform in neutrophils (47) to contaminating eosinophils (27) . When we used a similar approach to completely deplete eosinophils (and other leukocytes) from our neutrophil preparations, however, we found that highly purified neutrophils still express substantial amounts of C/EBP, even though eosinophils do express the protein as well (supplemental Fig. 3) . A possible explanation for this discrepancy is that different Abs were used to deplete eosinophils (anti-CD49d in the previous report vs anti-CD9 in our case). In this regard, it is noteworthy that the CD49d Ag is strongly expressed on the surface of neutrophil precursors and moderately on peripheral blood human neutrophils (48, 49) . It is therefore conceivable that a neutrophil subpopulation that strongly expresses C/EBP is removed when using anti-CD49d Abs to deplete eosinophils. Conversely, our demonstration that C/EBP is expressed in neutrophil-like PLB-985 cells (Fig. 5B) , which are not contaminated by eosinophil-like cells, is further evidence that human neutrophils do express C/EBP.
Having established which C/EBP isoforms are expressed in neutrophils, we next investigated their fate upon cell stimulation. Whereas the amount of some C/EBP proteins increases following stimulation in monocytes and macrophages (25, (33) (34) (35) (36) , the cellular content of most C/EBP proteins was unaffected by neutrophil stimulation by physiological agonists (i.e., LPS, TNF-␣) for up to 4 h. Even the constitutive, proteasome-mediated degradation of C/EBP␦ was unchanged in LPS-or TNF-treated neutrophils. The observation that C/EBP␦ is relatively short-lived prompted us to investigate the stability of other isoforms. In contrast to C/EBP␦, all other C/EBP proteins expressed in neutrophils were found to have a slow turnover, as their cellular levels were unaffected by cycloheximide, whether in resting or stimulated cells. We finally investigated the subcellular localization of C/EBP proteins in resting and activated neutrophils and found that most C/EBP isoforms are strictly nuclear, with the exception of C/EBP␣, and of the p14 FIGURE 9. Functional consequences of C/EBP␤ phosphorylation on cytokine production in neutrophil-like PLB-985 cells. Granulocytic PLB-985 cells (d5) were nucleofected with a plasmid encoding either C/EBP␤ variant or with an empty vector (pCDNA3). After a 2.5-h culture, the cells were stimulated for 6 h with 100 ng/ml LPS before ELISA analysis of culture supernatants. Mean Ϯ SEM from three independent experiments. ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01; ‫,ءءء‬ p Ͻ 0.001; ns, not significant. variant of C/EBP, which were cytoplasmic. Accordingly, we detected a constitutive C/EBP DNA-binding activity in nuclear extracts of both primary neutrophils and neutrophil-like PLB-985 cells. Supershift experiments established the prevalence of C/EBP␤ and within the specific C/EBP DNA-binding complex, in keeping with the fact that these two isoforms appear to be the most abundantly expressed in neutrophils. Unexpectedly, stimulation of neutrophils with either LPS or TNF-␣ failed to increase the intensity of the C/EBP DNA-binding complex in neutrophils, in contrast to observations made in other inflammatory cells, such as mouse macrophages (35) (36) (37) . In the latter instance, however, the increase in DNA binding largely reflects the de novo synthesis of C/EBP␤ and ␦ isoforms (35-37), whereas we showed herein that cellular C/EBP levels are unaffected by neutrophil stimulation.
From a more functional perspective, we showed that C/EBP␤ could be transiently phosphorylated on Thr 235 in response to stimulation with LPS or TNF-␣. Supershift experiments further established that C/EBP␤ phosphorylated on this residue was a constituent of the C/EBP DNA-binding complexes detected in nuclear extracts of stimulated neutrophils. Furthermore, we demonstrated that upon cell stimulation, C/EBP␤ phosphorylated on Thr 235 is recruited to the IL-8 proximal promoter in neutrophils. To our knowledge, this the first time that ChIP assays have been successfully performed in human neutrophils. Because C/EBP␤ phosphorylation on Thr 235 entails an increased potential to activate gene promoters (12) (13) (14) , we investigated whether C/EBP proteins can modulate cytokine expression in neutrophils. To this end, we used granulocytic PLB-985 cells, which we recently showed to behave like primary neutrophils with respect to transcription factor activation and inflammatory cytokine generation (8) . In this model, we showed that agonists that induce C/EBP␤ phosphorylation (LPS, TNF-␣) also stimulate the activity of a C/EBP-driven promoter, as well as that of an actual cytokine promoter (the IL-8 promoter). Moreover, the use of proximal IL-8 promoter variants mutated in the NF-B or C/EBP sites clearly demonstrated that these binding sites are crucial for IL-8 promoter transactivation in human granulocytes. To verify that the transcription factors binding to these sequences are indeed NF-B and C/EBP proteins, we overexpressed specific dominant negatives of either family (IB␣ (S32,36A) and A-CEBP2N3T, respectively) into granulocytic PLB-985 cells. These experiments confirmed our recent demonstration of the central role of NF-B in inducible cytokine expression in both granulocytic PLB-985 cells and primary neutrophils (5, 8) . More importantly, these overexpression experiments also established for the first time that C/EBP proteins play a crucial role in the inducible gene expression (and subsequent release) of several inflammatory chemokines. In this regard, the fact that A-CEBP2N3T overexpression potently inhibited IL-8, Mip-1␣, and Mip-1␤ generation is especially relevant, considering that GFP overexpression experiments indicated that only about two-thirds of the cells actually express the transfected material (8) . Thus, A-CEBP2N3T must have been tremendously effective in inhibiting downstream cellular responses in those cells that overexpressed it. This said, not all cytokines investigated were under the control of C/EBP proteins, as illustrated by our finding that TNF-␣ gene expression and release were only modestly affected by A-CEBP2N3T overexpression. Finally, overexpression of a C/EBP␤ mutant (T235A) confirmed the importance of C/EBP␤ phosphorylation on Thr 235 for the inducible generation of several cytokines in human granulocytes.
Collectively, our findings represent the first demonstration of C/EBP protein involvement in the expression and production of inflammatory cytokines (or any protein) in mature human granulocytes. As our study was being completed, Akagi and colleagues (50) reported that in neutrophils from C/EBP␤ knockout mice, the expression of IL-6, IL-10, and IL-12 were strongly decreased following LPS stimulation, relative to wild-type mice (50) . This suggests that these cytokines, and perhaps others that are also relevant to inflammatory and immune processes, might be similarly controlled by C/EBP proteins in human neutrophils, in addition to IL-8, Mip-1␣, and Mip-1␤ (as shown herein). This will be addressed in future studies. Another important aspect of our findings is that nuclear C/EBP complexes are constitutively present in neutrophils, and that promoter activation results from inducible C/EBP␤ phosphorylation, as opposed to increased DNA binding. This agrees well with our observations that C/EBP␤ and C/EBP constitutively bind to the IL-8 proximal promoter in primary human neutrophils, and that phosphorylated C/EBP␤ is recruited to this promoter region upon cell stimulation. A constitutive association of C/EBP␤ with the RANTES and the IL-1␤ promoters was similarly reported to remain unchanged in stimulated Mono Mac 6 human monocytes, yet C/EBP factors were found to be necessary for LPS-induced gene expression in this model (51, 52) . Taken together, the above considerations indicate that in human neutrophils, genes encoding inflammatory cytokines and chemokines might be similarly transcribed from a poised promoter architecture due to posttranslational modification of C/EBP␤ and perhaps other transcription factors. Future studies are clearly required to elucidate this possibility. On a final note, our data suggest that C/EBP proteins might represent a potentially interesting therapeutic target, especially in disorders in which neutrophils prevail. One possible advantage of such an approach is that C/EBP proteins are involved in the induction of a smaller subset of inflammatory mediators than those under the control of NF-B transcription factors, which should help minimize undesired side effects.
